Τίτλος:
Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objective: The expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance as somatostatin analogues and dopamine agonists can be used for their localization and/or treatment. The objective of this study is to examine the expression of the five SSTR subtypes and DR2 in lung carcinoids (LCs). Methods: We conducted a retrospective study of 119 LCs from 106 patients [typical carcinoids (TCs): n = 100, and atypical carcinoids (ACs): n = 19]. The expression of all five SSTR subtypes and DR2 was evaluated immunohistochemically and correlated to clinicopathological data. In a subgroup of cases, receptor expression was further analyzed using semiquantitative RT-PCR. Results: SSTR2A was the SSTR subtype most frequently expressed immunohistochemically (72%), followed by SSTR1 (63%), SSTR5 (40%), and SSTR3 (20%), whereas SSTR4 was negative. DR2 was expressed in 74% and co-expressed with SSTR1 in 56%, with SSTR2A in 59%, with SSTR3 in 19%, and with SSTR5 in 37% of the tumors. Receptor expression was not related to the histological subtype, tumor aggressiveness (disease extent/grading) or functionality; however, DR2 was expressed more frequently in ACs than TCs (95 vs. 70%, p = 0.017). In a subset of patients, RT-PCR findings highly suggested that the expression of SSTR2A, SSTR3, DR2, and to a lesser extent that of SSTR1 and SSTR5 is the outcome of increased gene transcription. Conclusions: The high and variable immunohistochemical expression of the majority of SSTRs along with their co-expression with DR2 in LCs provides a rationale for their possible treatment with agents that target these receptors. © 2015 S. Karger AG, Basel.
Συγγραφείς:
Kanakis, G.
Grimelius, L.
Spathis, A.
Tringidou, R.
Rassidakis, G.Z.
Öberg, K.
Kaltsas, G.
Tsolakis, A.V.
Περιοδικό:
ISRN Neuroendocrinology
Λέξεις-κλειδιά:
dopamine receptor; dopamine receptor 2; somatostatin receptor 1; somatostatin receptor 2; somatostatin receptor 3; somatostatin receptor 4; somatostatin receptor 5; unclassified drug; dopamine 2 receptor; somatostatin receptor; somatostatin receptor 3; somatostatin receptor 5; somatostatin receptor subtype 2, human; somatostatin receptor subtype-4; somatostatin receptor type 1; tumor protein, adenohypophysis; adolescent; adult; aged; Article; cancer therapy; carcinoid; clinical evaluation; clinical feature; controlled study; correlation analysis; distant metastasis; female; genetic transcription; human; human tissue; hypophysis adenoma; immunohistochemistry; lung cancer; lung carcinoid; lymph node metastasis; major clinical study; male; neuroendocrine tumor; pancreas tumor; priority journal; protein expression; quantitative analysis; real time polymerase chain reaction; retrospective study; statistical analysis; carcinoid; genetics; lung tumor; metabolism; middle aged; pathology, Carcinoid Tumor; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Receptors, Dopamine D2; Receptors, Somatostatin; Retrospective Studies
